A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Avalo Therapeutics, Inc.
AVTX
$247M
Mkt Cap
$18.44
+3.83%
Avalo Therapeutics, Inc. (AVTX) has a 5-year average return on invested capital (ROIC) of -88.3%. This is below average and may indicate limited pricing power.
Avalo Therapeutics, Inc. (AVTX) has a market capitalization of $247M. It is classified as a small-cap stock.
Avalo Therapeutics, Inc. (AVTX) does not currently pay a regular dividend.
Avalo Therapeutics, Inc. (AVTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Avalo Therapeutics, Inc. (AVTX) generated $-51 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Avalo Therapeutics, Inc. (AVTX) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Avalo Therapeutics, Inc. (AVTX) reported earnings per share (EPS) of $-5.84 in its most recent fiscal year.
Table of Contents PART I Avalo Therapeutics, Inc. (the “Company”, “Avalo” or “we”) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β monoclonal antibody (“mAb”), targeting inflammatory diseases. Avalo was incorporated in Delaware and commenced operation in 2011, and completed its initial public offering in October 2015. Our Strategy Our strategy for increasing stockholder value includes: •Advancing our pipeline through development to regulatory approval.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 1.9M | - | - |
| Net Income | -78M | -78M | -35M | - | -42M | -84M |
| EPS | $-5.84 | $-5.84 | $-3.35 | $-2,112.59 | $-1,971.90 | $-200.36 |
| Free Cash Flow | -51M | -51M | -49M | -31M | -27M | -71M |
| ROIC | -85.2% | -72.4% | -50.1% | - | -142.5% | -1532.9% |
| Gross Margin | - | - | - | 33.3% | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.26 | -2.06 | 1.55 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -73M | -73M | -69M | -27M | -37M | -82M |
| Operating Margin | 0.0% | - | - | -1421.6% | - | - |
| ROE | -94.2% | -72.4% | -50.1% | - | - | -354.2% |
| Shares Outstanding | 13M | 13M | 10M | 0M | 0M | 0M |
| Metric | 2014 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 0 | 0 | N/A | 28M | N/A | N/A | N/A | N/A | N/A | 1.9M | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | 97.7% | N/A | N/A | N/A | N/A | N/A | 33.3% | N/A | N/A | N/A |
| R&D | 12M | 6.6M | 10M | 4.4M | 5.8M | 12M | 32M | 60M | 31M | 14M | 24M | 50M | 50M |
| SG&A | 4.9M | 4.4M | 7.1M | 7.9M | 11M | 10M | 17M | 25M | 21M | 10M | 17M | 23M | 23M |
| EBIT | -17M | -11M | -16M | 14M | -35M | -16M | -73M | -82M | -37M | -27M | -69M | -73M | -73M |
| Op. Margin | N/A | N/A | N/A | 49.9% | N/A | N/A | N/A | N/A | N/A | -1421.6% | N/A | N/A | 0.0% |
| Net Income | N/A | -10M | -16M | 7.8M | 42M | -16M | -64M | -84M | -42M | N/A | -35M | -78M | -78M |
| Net Margin | N/A | N/A | N/A | 27.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | -18K | 0 | 0 | 0 | 1.9M | 1.4M | 0 | 0 | 0 | 3.9M | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | N/A | -50.8% | N/M | 97.2% | 132.2% | -57.2% | N/M | N/M | -142.5% | N/A | -50.1% | -72.4% | -85.2% |
| ROE | N/A | 158.4% | -247.9% | 55.4% | 171.0% | -76.7% | -278.8% | -354.2% | N/A | N/A | -50.1% | -72.4% | -94.2% |
| ROA | N/A | -61.8% | -120.1% | 32.0% | 73.8% | -30.2% | -159.0% | -136.1% | -73.4% | N/A | -40.9% | -58.6% | -67.2% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -16M | -10M | -15M | 13M | -3.1M | -19M | -41M | -71M | -27M | -31M | -49M | -51M | -51M |
| Free Cash Flow | -16M | -10M | -15M | 13M | -3.7M | -19M | -41M | -71M | -27M | -31M | -49M | -51M | -51M |
| Owner Earnings | -17M | -11M | -16M | 11M | -10M | -26M | -49M | -81M | -34M | -34M | -55M | -65M | -65M |
| CapEx | 20K | 20K | 35K | 23K | 564K | 262K | 63K | 113K | 95K | 158K | 0 | 0 | 0 |
| Maint. CapEx | 37K | 24K | 27K | 425K | 4.6M | 3.9M | 1.8M | 1.7M | 166K | 158K | 169K | 344K | 344K |
| Growth CapEx | 0 | 0 | 8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A | 0 |
| D&A | 37K | 24K | 27K | 425K | 4.6M | 3.9M | 1.8M | 1.7M | 166K | 158K | 169K | 344K | 344K |
| CapEx/OCF | N/A | N/A | N/A | 0.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 1.1M | 395K | 1.7M | 1.2M | 2.4M | 2.5M | 6.8M | 8.2M | 7.6M | 3.5M | 5.9M | 14M | 14M |
| Debt Repayment | 0 | 1.8M | 3.3M | 2.4M | 0 | 256K | 0 | 0 | 0 | 21M | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -2.3M | -16M | -2.8M | -2.5M | 4.7M | -2.3M | -17M | -19M | 9.3M | -5.5M | -134M | -98M | -15M |
| Cash & Equiv. | 12M | 21M | 5.1M | 2.5M | 11M | 3.6M | 19M | 55M | 13M | 7.4M | 135M | 16M | 16M |
| Long-Term Debt | 5.3M | 2.4M | 0 | 0 | 14M | 0 | 0 | 33M | 13M | 0 | N/A | N/A | 427K |
| Debt/Equity | -0.36 | 0.43 | 11.37 | 0.00 | 0.74 | 0.06 | 0.06 | 1.55 | -2.06 | 0.26 | 0.01 | 0.01 | 0.01 |
| Interest Coverage | -98.6 | -19.4 | -46.1 | 191.5 | -67.4 | -15.4 | N/A | -51.8 | -12.8 | -14.2 | N/A | N/A | N/A |
| Equity | -26M | 13M | 207K | 28M | 21M | 21M | 25M | 23M | -11M | 7.3M | 133M | 83M | 83M |
| Total Assets | 12M | 22M | 5.8M | 43M | 70M | 36M | 44M | 80M | 33M | 21M | 151M | 116M | 116M |
| Total Liabilities | 10M | 8.6M | 5.6M | 15M | 49M | 15M | 19M | 57M | 44M | 14M | 18M | 33M | 33M |
| Intangibles | N/A | N/A | 0 | 18M | 3.8M | 2.4M | 1.6M | 38K | 0 | N/A | N/A | N/A | N/A |
| Retained Earnings | -43M | -54M | -70M | -58M | -98M | -114M | -178M | -262M | -304M | -335M | -370M | -449M | -449M |
| Working Capital | 7.2M | 16M | 1.4M | -415K | -4.3M | 5.6M | 11M | 42M | -5.7M | 3.8M | 132M | 92M | 92M |
| Current Assets | 12M | 22M | 5.7M | 11M | 22M | 18M | 26M | 62M | 16M | 8.4M | 139M | 105M | 105M |
| Current Liabilities | 5.0M | 5.8M | 4.3M | 11M | 26M | 12M | 15M | 20M | 22M | 4.6M | 7.0M | 13M | 13M |
| Per Share Data | |||||||||||||
| EPS | -15,782.40 | -13.53 | -20.87 | 9.37 | 22.81 | -8.08 | -18.90 | -200.36 | -1,971.90 | -2,112.59 | -3.35 | -5.84 | -5.84 |
| Owner EPS | -73,769.67 | -13.65 | -20.65 | 13.26 | -5.53 | -12.85 | -14.63 | -191.68 | -1,631.70 | -796.09 | -5.26 | -4.88 | -4.88 |
| Book Value | -116,715.19 | 16.88 | 0.26 | 33.60 | 11.44 | 10.56 | 7.31 | 54.81 | -516.67 | 169.45 | 12.70 | 6.20 | 6.20 |
| Cash Flow/Share | -68,787.75 | -13.11 | -18.46 | 15.17 | -1.71 | -9.62 | -12.06 | -168.34 | -1,266.27 | -711.76 | -4.68 | -3.84 | -5.81 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.0M | 0.8M | 0.8M | 0.8M | 1.8M | 2.0M | 3.4M | 0.4M | 0.0M | 0.0M | 10.5M | 13.4M | 13.4M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | 7.9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -3.2 |
| P/FCF | N/A | N/A | N/A | 633.3 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | 4.3 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 137.9 | 2.2 | 5.0 | 21.8 | 12.6 | 11.6 | N/A | 17.2 | 0.7 | N/A | 3.0 |
| Price/Sales | N/A | N/A | N/A | 0.6 | N/A | N/A | N/A | N/A | 92.2 | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -51.2% | 20.4% | -3.5% | -4.2% | -13.1% | -26.5% | -2.1% | -24.6% | -55.2% | N/A | -20.8% |
| Market Cap | 0 | 0 | 29M | 62M | 105M | 457M | 310M | 268M | 1.3B | 126M | 89M | 0 | 247M |
| Avg. Price | 0.00 | 0.00 | 9,701.41 | 2,591.99 | 11,852.43 | 12,874.11 | 8,118.97 | 7,998.55 | 1,609.01 | 390.66 | 9.90 | 0.00 | 18.44 |
| Year-End Price | 0.00 | 0.00 | 2,620.80 | 9,590.40 | 9,043.20 | 14,774.40 | 7,920.00 | 4,867.20 | 1,233.60 | 11.76 | 8.33 | 0.00 | 18.44 |
Avalo Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 33.3%.
Avalo Therapeutics, Inc. (AVTX) has a return on equity (ROE) of -72.4%. A negative ROE may indicate losses or negative equity.
Avalo Therapeutics, Inc. (AVTX) has a 5-year average gross margin of 33.3%. This indicates decent pricing power.
The Ledger Terminal provides 12 years of financial data for Avalo Therapeutics, Inc. (AVTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Avalo Therapeutics, Inc. (AVTX) has a book value per share of $6.20, based on its most recent annual SEC filing.